IRAK3
Basic information
Region (hg38): 12:66189195-66254622
Links
Phenotypes
GenCC
Source:
- asthma-related traits, susceptibility to, 5 (Limited), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (78 variants)
- not_provided (14 variants)
- IRAK3-related_disorder (11 variants)
- Asthma-related_traits,_susceptibility_to,_5 (2 variants)
- Susceptibility_to_severe_COVID-19 (1 variants)
- Hirschsprung_disease,_susceptibility_to,_1 (1 variants)
- Multisystem_inflammatory_syndrome_in_children (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IRAK3 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000007199.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | |||||
| missense | 76 | 84 | ||||
| nonsense | 5 | |||||
| start loss | 1 | 1 | ||||
| frameshift | 4 | |||||
| splice donor/acceptor (+/-2bp) | 2 | |||||
| Total | 0 | 2 | 83 | 13 | 5 |
Highest pathogenic variant AF is 0.00001163241
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| IRAK3 | protein_coding | protein_coding | ENST00000261233 | 12 | 65744 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 5.31e-21 | 0.000403 | 125383 | 1 | 364 | 125748 | 0.00145 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -0.0745 | 315 | 311 | 1.01 | 0.0000153 | 3929 |
| Missense in Polyphen | 89 | 101.7 | 0.87511 | 1329 | ||
| Synonymous | 0.637 | 104 | 113 | 0.924 | 0.00000553 | 1089 |
| Loss of Function | -0.643 | 29 | 25.5 | 1.14 | 0.00000122 | 333 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.00588 | 0.00588 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00169 | 0.00169 |
| Finnish | 0.0000925 | 0.0000924 |
| European (Non-Finnish) | 0.000793 | 0.000791 |
| Middle Eastern | 0.00169 | 0.00169 |
| South Asian | 0.00101 | 0.00101 |
| Other | 0.00163 | 0.00163 |
dbNSFP
Source:
- Function
- FUNCTION: Inhibits dissociation of IRAK1 and IRAK4 from the Toll- like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex. {ECO:0000250|UniProtKB:Q8K4B2, ECO:0000269|PubMed:10383454}.;
- Pathway
- Neurotrophin signaling pathway - Homo sapiens (human);Regulation of toll-like receptor signaling pathway;IL-1 signaling pathway;Signaling by Interleukins;signal transduction through il1r;Cytokine Signaling in Immune system;Toll-Like Receptors Cascades;Interleukin-1 signaling;Innate Immune System;Immune System;IL1;Toll Like Receptor 4 (TLR4) Cascade;MyD88:Mal cascade initiated on plasma membrane;Toll Like Receptor TLR1:TLR2 Cascade;Toll Like Receptor TLR6:TLR2 Cascade;Toll Like Receptor 2 (TLR2) Cascade;IL1-mediated signaling events;Interleukin-1 family signaling
(Consensus)
Recessive Scores
- pRec
- 0.209
Intolerance Scores
- loftool
- 0.982
- rvis_EVS
- -0.35
- rvis_percentile_EVS
- 29.54
Haploinsufficiency Scores
- pHI
- 0.127
- hipred
- N
- hipred_score
- 0.394
- ghis
- 0.548
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.941
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Irak3
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; hematopoietic system phenotype; endocrine/exocrine gland phenotype; limbs/digits/tail phenotype; immune system phenotype; skeleton phenotype;
Zebrafish Information Network
- Gene name
- irak3
- Affected structure
- blood cell
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- negative regulation of cytokine-mediated signaling pathway;MyD88-dependent toll-like receptor signaling pathway;protein phosphorylation;response to virus;positive regulation of macrophage tolerance induction;negative regulation of macrophage cytokine production;cytokine-mediated signaling pathway;negative regulation of NF-kappaB transcription factor activity;response to peptidoglycan;response to lipopolysaccharide;negative regulation of interleukin-12 production;negative regulation of interleukin-6 production;negative regulation of tumor necrosis factor production;negative regulation of toll-like receptor signaling pathway;intracellular signal transduction;negative regulation of protein catabolic process;negative regulation of protein complex disassembly;regulation of protein complex disassembly;response to exogenous dsRNA;negative regulation of MAP kinase activity;negative regulation of innate immune response;protein autophosphorylation;positive regulation of NF-kappaB transcription factor activity;interleukin-1-mediated signaling pathway;response to interleukin-1
- Cellular component
- nucleus;cytoplasm;plasma membrane
- Molecular function
- magnesium ion binding;protein serine/threonine kinase activity;ATP binding;protein homodimerization activity;protein heterodimerization activity